William J Meurer1, Jason T Connor2,3, Jeffrey Glassberg4. 1. a Departments of Emergency Medicine and Neurology , University of Michigan , Ann Arbor , MI , USA. 2. b Berry Consultants , Austin , TX , USA. 3. c University of Central Florida College of Medicine , Orlando , FL , USA. 4. d Departments of Emergency Medicine, Hematology and Medical Oncology , Icahn School of Medicine at Mount Sinai , New York , NY , USA.
Abstract
OBJECTIVE: To use numerical simulation to evaluate various randomization strategies for a clinical trial in sickle cell disease (SCD). METHODS: The Inhaled Mometasone to Promote Reduction in Vaso-occlusive Events trial* is a randomized, controlled, feasibility study of inhaled mometasone for individuals with SCD who do not have asthma. The target sample size is 45 patients and one goal is to limit imbalance with respect to two important covariates (1) hydroxyurea use and (2) historical emergency department (ED) utilization. We compared three methods of patient allocation (simple randomization, block randomization, and biased-coin adaptive randomization) using numerical simulation (10 000 trials). The primary outcome measure was the proportion of simulated trials with numerically apparent differences in the two covariates: hydroxyurea use (binary) and ED utilization (three-level ordinal). RESULTS: Overall, only 1.6% of simulated trials had any covariate comparison with P < 0.3 across groups for simple randomization, and 0% for both the block and adaptive randomization. In trials where the total sample size was 45 patients, the block randomization strategy achieved the greatest balance because participants were deterministically assigned to the treatment arm that balanced covariates. The adaptive strategy achieved similar results without deterministic treatment assignments even when trials included only 45 patients. DISCUSSION: Adaptive clinical trial designs have potential to mitigate some of the challenges that have hampered SCD trials. In small exploratory trials, even non-statistically significant differences in important covariates can threaten interpretability and external validity. CONCLUSION: Adaptive randomization performed similarly to block randomization and offers advantages including better allocation concealment and less ability for investigators to predict the next assignment.
RCT Entities:
OBJECTIVE: To use numerical simulation to evaluate various randomization strategies for a clinical trial in sickle cell disease (SCD). METHODS: The Inhaled Mometasone to Promote Reduction in Vaso-occlusive Events trial* is a randomized, controlled, feasibility study of inhaled mometasone for individuals with SCD who do not have asthma. The target sample size is 45 patients and one goal is to limit imbalance with respect to two important covariates (1) hydroxyurea use and (2) historical emergency department (ED) utilization. We compared three methods of patient allocation (simple randomization, block randomization, and biased-coin adaptive randomization) using numerical simulation (10 000 trials). The primary outcome measure was the proportion of simulated trials with numerically apparent differences in the two covariates: hydroxyurea use (binary) and ED utilization (three-level ordinal). RESULTS: Overall, only 1.6% of simulated trials had any covariate comparison with P < 0.3 across groups for simple randomization, and 0% for both the block and adaptive randomization. In trials where the total sample size was 45 patients, the block randomization strategy achieved the greatest balance because participants were deterministically assigned to the treatment arm that balanced covariates. The adaptive strategy achieved similar results without deterministic treatment assignments even when trials included only 45 patients. DISCUSSION: Adaptive clinical trial designs have potential to mitigate some of the challenges that have hampered SCD trials. In small exploratory trials, even non-statistically significant differences in important covariates can threaten interpretability and external validity. CONCLUSION: Adaptive randomization performed similarly to block randomization and offers advantages including better allocation concealment and less ability for investigators to predict the next assignment.
Authors: Jeffrey Glassberg; John F Spivey; Robert Strunk; Sara Boslaugh; Michael R DeBaun Journal: J Pediatr Hematol Oncol Date: 2006-08 Impact factor: 1.289
Authors: Robyn T Cohen; Anusha Madadi; Morey A Blinder; Michael R DeBaun; Robert C Strunk; Joshua J Field Journal: Am J Hematol Date: 2011-08-02 Impact factor: 10.047
Authors: Marlene H Peters-Lawrence; Margaret C Bell; Lewis L Hsu; Ifeyinwa Osunkwo; Phillip Seaman; Miren Blackwood; Edouard Guillaume; Rita Bellevue; Lakshmanan Krishnamurti; Wally R Smith; Carlton D Dampier; Caterina P Minniti Journal: Contemp Clin Trials Date: 2011-12-02 Impact factor: 2.226
Authors: Jeffrey A Glassberg; Annie Chow; Juan Wisnivesky; Ronald Hoffman; Michael R Debaun; Lynne D Richardson Journal: Br J Haematol Date: 2012-09-12 Impact factor: 6.998
Authors: Jeffrey Glassberg; Caterina Minnitti; Caroline Cromwell; Lawrence Cytryn; Thomas Kraus; Gwen S Skloot; Jason T Connor; Adeeb H Rahman; William J Meurer Journal: Am J Hematol Date: 2017-06-05 Impact factor: 10.047